Fig. 1

Proportion (95% CI) of patients achieving ACR responses at month 3. The plots show (A) ACR20, (B) ACR50, and (C) ACR70 response rates. Data presented for the FAS; non responder imputation. Non-MTX csDMARD-IR (i.e., non-MTX csDMARD-IR but not bDMARD-IR) FAS: tofacitinib 5 mg BID, n = 202; tofacitinib 10 mg BID, n = 219; placebo, n = 52. MTX-IR (i.e., MTX-IR but not bDMARD-IR) FAS: tofacitinib 5 mg BID, n = 1072; tofacitinib 10 mg BID, n = 1102; placebo, n = 631. bDMARD-IR FAS: tofacitinib 5 mg BID, n = 258; tofacitinib 10 mg BID, n = 251; placebo, n = 191. ACR20/50/70 American College of Rheumatology ≥ 20/50/70% response criteria, bDMARD biologic disease-modifying antirheumatic drug, BID twice daily, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, FAS full analysis set, IR inadequate response or intolerance, MTX methotrexate